相似文献
1
Gemcitabine improves survival in patients with recurrent or metastatic nasopharyngeal carcinoma.
Chin J Cancer. 2016 Dec 22;35(1):100. doi: 10.1186/s40880-016-0163-6.
2
Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial.
Lancet. 2016 Oct 15;388(10054):1883-1892. doi: 10.1016/S0140-6736(16)31388-5. Epub 2016 Aug 23.
3
Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin for first-line treatment of recurrent or metastatic nasopharyngeal carcinoma.
Oral Oncol. 2019 Jul;94:80-85. doi: 10.1016/j.oraloncology.2019.04.022. Epub 2019 May 22.
4
Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study.
J Clin Oncol. 2021 Oct 10;39(29):3273-3282. doi: 10.1200/JCO.21.00396. Epub 2021 Aug 11.
5
Nab-paclitaxel, cisplatin, and capecitabine versus cisplatin and gemcitabine as first line chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma: randomised phase 3 clinical trial.
BMJ. 2024 Jun 19;385:e077890. doi: 10.1136/bmj-2023-077890.
6
A Phase II trial of erlotinib as maintenance treatment after gemcitabine plus platinum-based chemotherapy in patients with recurrent and/or metastatic nasopharyngeal carcinoma.
Am J Clin Oncol. 2012 Jun;35(3):255-60. doi: 10.1097/COC.0b013e31820dbdcc.
7
Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials.
Lancet Oncol. 2018 Oct;19(10):1338-1350. doi: 10.1016/S1470-2045(18)30495-9. Epub 2018 Sep 10.
8
Gemcitabine and Cisplatin followed by chemo-radiation for advanced nasopharyngeal carcinoma.
Asian Pac J Cancer Prev. 2014;15(2):899-904. doi: 10.7314/apjcp.2014.15.2.899.
9
Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin in the first-line setting for Chinese patients with metastatic nasopharyngeal carcinoma.
Eur Arch Otorhinolaryngol. 2020 Feb;277(2):577-584. doi: 10.1007/s00405-019-05714-z. Epub 2019 Nov 12.
10
A phase 2 trial of gemcitabine plus toripalimab for cisplatin-ineligible patients with recurrent or metastatic nasopharyngeal carcinoma.
Cell Rep Med. 2024 Oct 15;5(10):101779. doi: 10.1016/j.xcrm.2024.101779.
引用本文的文献
1
Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study.
J Clin Oncol. 2021 Oct 10;39(29):3273-3282. doi: 10.1200/JCO.21.00396. Epub 2021 Aug 11.
2
Hepatic artery infusion pump for nasopharyngeal carcinoma with liver metastasis.
Clin Exp Metastasis. 2020 Apr;37(2):333-339. doi: 10.1007/s10585-019-10015-0. Epub 2019 Dec 20.
3
Current Immune-Related Molecular Approach in Combating Nasopharyngeal Cancer.
World J Oncol. 2019 Oct;10(4-5):157-161. doi: 10.14740/wjon1214. Epub 2019 Sep 20.
本文引用的文献
1
Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial.
Lancet. 2016 Oct 15;388(10054):1883-1892. doi: 10.1016/S0140-6736(16)31388-5. Epub 2016 Aug 23.
2
Long-term outcomes of a phase II randomized controlled trial comparing intensity-modulated radiotherapy with or without weekly cisplatin for the treatment of locally recurrent nasopharyngeal carcinoma.
Chin J Cancer. 2016 Feb 15;35:20. doi: 10.1186/s40880-016-0081-7.
3
Development and External Validation of Nomograms for Predicting Survival in Nasopharyngeal Carcinoma Patients after Definitive Radiotherapy.
Sci Rep. 2015 Oct 26;5:15638. doi: 10.1038/srep15638.
4
Nasopharyngeal carcinoma.
Lancet. 2016 Mar 5;387(10022):1012-1024. doi: 10.1016/S0140-6736(15)00055-0. Epub 2015 Aug 28.
5
Incidence trend of nasopharyngeal carcinoma from 1987 to 2011 in Sihui County, Guangdong Province, South China: an age-period-cohort analysis.
Chin J Cancer. 2015 May 14;34(8):350-7. doi: 10.1186/s40880-015-0018-6.
6
Nasopharyngeal carcinoma incidence and mortality in China in 2010.
Chin J Cancer. 2014 Aug;33(8):381-7. doi: 10.5732/cjc.014.10086.
7
Comparison of five cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma.
J Cancer Res Clin Oncol. 2012 Oct;138(10):1717-25. doi: 10.1007/s00432-012-1219-x. Epub 2012 Jun 10.
8
Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225.
J Clin Oncol. 2009 Aug 1;27(22):3684-90. doi: 10.1200/JCO.2008.19.9109. Epub 2009 Jun 29.
Zotero 插件